1. Association of circulating factor seven activating protease (FSAP) and of oral Omega-3 fatty acids supplements with clinical outcome in patients with atrial fibrillation: the OMEGA-AF study.
- Author
-
Parahuleva MS, Kanse S, Hölschermann H, Zheleva K, Zandt D, Worsch M, Parviz B, Güttler N, Tillmanns H, Böning A, and Erdogan A
- Subjects
- Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Atrial Fibrillation blood, Atrial Fibrillation diet therapy, Dietary Supplements, Fatty Acids, Omega-3 administration & dosage, Serine Endopeptidases blood
- Abstract
Factor VII Activating Protease (FSAP) activates factor VII (FVII) as well as pro-urokinase (uPA). Our goal was to evaluate the relation between plasma levels of FSAP and clinical instability in atrial fibrillation (AF) and possible effects of oral omega-3 fatty acids (FA) supplements. 101 patients with persistent AF were analyzed in the OMEGA-AF Study. Plasma FSAP levels were measured at baseline and after 12 weeks of treatment with omega-3 FA. The median FSAP antigen concentration, in contrast to FSAP activity, was higher in patients with persistent AF. The maintenance of SR after successful cardioversion (CV) did not lead to a normalization of FSAP concentration. Supplementation with omega-3 FA but not placebo significantly reduced elevated FSAP concentration. Furthermore, elevated FSAP levels did not indicate a significantly increased risk of recurrence of AF after electrical CV or cardiovascular clinical events during 1 year of follow-up. Plasma FSAP concentration was increased in patients with AF and may be involved in the pathogenesis of this condition. The possible effects of omega-3 FA on clinical AF potential could be linked with modulation of circulating FSAP levels.
- Published
- 2014
- Full Text
- View/download PDF